Guerbet logo
GBT logo

GuerbetENXTPA:GBT Stock Report

Market Cap €331.0m
Share Price
n/a
1Y-11.0%
7D5.1%
Portfolio Value
​
View

Guerbet SA

ENXTPA:GBT Stock Report

Market Cap: €331.0m

GBT Stock Overview

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. More details

GBT fundamental analysis
Snowflake Score
Valuation6/6
Future Growth2/6
Past Performance2/6
Financial Health4/6
Dividends2/6

Rewards

Trading at 70.9% below our estimate of its fair value

Earnings are forecast to grow 18.06% per year

Became profitable this year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 46.8%

Risk Analysis

Debt is not well covered by operating cash flow


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Guerbet SA Competitors

Amplitude Surgical

ENXTPA:AMPLI

€162.1m

LNA Santé

ENXTPA:LNA

€265.9m

Equasens Société anonyme

ENXTPA:EQS

€569.7m

Cegedim

ENXTPA:CGM

€185.1m

Price History & Performance

Summary of share price highs, lows and changes for Guerbet
Historical stock prices
Current Share Price€26.65
52 Week High€40.25
52 Week Low€24.25
Beta0.78
1 Month Change-3.09%
3 Month Change1.72%
1 Year Change-11.02%
3 Year Change-6.49%
5 Year Change-21.04%
Change since IPO168.26%

Recent News & Updates

Guerbet SA (EPA:GBT) Might Not Be As Mispriced As It Looks After Plunging 29%

Nov 16
Guerbet SA (EPA:GBT) Might Not Be As Mispriced As It Looks After Plunging 29%

Recent updates

Guerbet SA (EPA:GBT) Might Not Be As Mispriced As It Looks After Plunging 29%

Nov 16
Guerbet SA (EPA:GBT) Might Not Be As Mispriced As It Looks After Plunging 29%

Is Guerbet (EPA:GBT) Using Too Much Debt?

Apr 27
Is Guerbet (EPA:GBT) Using Too Much Debt?

Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

Feb 29
Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture

Feb 11
Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture

Guerbet SA (EPA:GBT) Screens Well But There Might Be A Catch

Jan 15
Guerbet SA (EPA:GBT) Screens Well But There Might Be A Catch

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Jul 22
The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Guerbet SA's (EPA:GBT) Intrinsic Value Is Potentially 92% Above Its Share Price

Jul 27
Guerbet SA's (EPA:GBT) Intrinsic Value Is Potentially 92% Above Its Share Price

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Mar 28
Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Is Guerbet (EPA:GBT) A Risky Investment?

Oct 25
Is Guerbet (EPA:GBT) A Risky Investment?

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Sep 23
The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

May 27
Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

May 04
We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Apr 05
Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 19
Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

Mar 01
What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

When Should You Buy Guerbet SA (EPA:GBT)?

Feb 10
When Should You Buy Guerbet SA (EPA:GBT)?

How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 28
How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Jan 13
Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

Dec 23
Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Dec 11
We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?

Nov 27
Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?

Shareholder Returns

GBTFR Medical EquipmentFR Market
7D5.1%5.7%2.1%
1Y-11.0%49.8%2.9%

Return vs Industry: GBT underperformed the French Medical Equipment industry which returned 49.8% over the past year.

Return vs Market: GBT underperformed the French Market which returned 2.9% over the past year.

Price Volatility

Is GBT's price volatile compared to industry and market?
GBT volatility
GBT Average Weekly Movement4.5%
Medical Equipment Industry Average Movement6.2%
Market Average Movement4.4%
10% most volatile stocks in FR Market10.1%
10% least volatile stocks in FR Market2.3%

Stable Share Price: GBT has not had significant price volatility in the past 3 months compared to the French market.

Volatility Over Time: GBT's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19262,920David Halewww.guerbet.com

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.

Guerbet SA Fundamentals Summary

How do Guerbet's earnings and revenue compare to its market cap?
GBT fundamental statistics
Market cap€330.99m
Earnings (TTM)€32.76m
Revenue (TTM)€840.79m

10.3x

P/E Ratio

0.4x

P/S Ratio

Is GBT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GBT income statement (TTM)
Revenue€840.79m
Cost of Revenue€211.73m
Gross Profit€629.06m
Other Expenses€596.30m
Earnings€32.76m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Mar 26, 2025

Earnings per share (EPS)2.60
Gross Margin74.82%
Net Profit Margin3.90%
Debt/Equity Ratio98.3%

How did GBT perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

19%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 19:00
End of Day Share Price 2025/02/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Guerbet SA is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laurent GelebartBNP Paribas Exane
Arnaud CadartCIC Market Solutions (ESN)
Robin LeclercDegroof Petercam